DNAPrint Genomics 'Solves' Human Eye Color and Announces the Development of First Commercial Product. SARASOTA, Fla., Oct 29, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc.(OTC Bulletin Board: DNAP) announced today that its scientists ha (RETINOME(SM)is capable of using a DNA specimen to predict the degree to which anindividual's retinas are pigmented with over 96% accuracy. Until now, forensicDNA testing has only been able to produce "bar- code like" data from DNA, whichis limited in utility for matching a DNA specimen with another previouslyderived from the same donor. If not matched to another previously obtainedresult, current tests are of limited use because they reveal no qualitativeinformation about the donor (such as eye color, hair color, skin shade, weightor height). DNAPrint believes its new RETINOME(SM) product is the firstcomprehensive genetic test capable of revealing qualitative trait informationfrom human DNA. As a new forensics tool, RETINOME(SM) could help law enforcementtarget investigations and provide probable cause for requesting a standard DNAtest from criminal suspects. As a research tool, RETINOME(SM) could acceleratedrug development for pigmentation related diseases such as cataracts andmelanoma.DNAPrint has filed a U.S. patent application (US patent pending serial NO.60/300,187) covering the composition of matter and methods related to theRETINOME(SM) discovery. The company has also submitted a manuscript describingthe "solution" to a major scientific journal. The solution incorporates compoundgenotypes from five haplotype systems in four different genes. The four geneswere previously known from genetics of human diseases (such as oculocutaneousalbinism) to be involved in the synthesis of the main pigment (eumelanin)responsible for the coloration of human tissues. However, two of the four geneswere not previously known to be specifically involved in retinal pigmentation.DNAPrint scientists first discovered numerous SNPs in a number of candidategenes using proprietary discovery protocols and software. Haplotypesincorporating a subset of these SNPs, in a subset of these genes, were thenassembled and linked to various eye color shades with a high degree ofstatistical certainty (average p[haplotype system at the population level]=0.007). The company then applied proprietary and third-party computationalmethods to assemble these haplotypes into a classification "solution" ofcompound genotypes that explained most of the variation in natural eye colorshade in the project study group (n=276). Previous attempts to "solve" variableeye color by others had been hampered by the inter- and intra-genic complexityof the trait. DNAPrint was able to overcome these challenges using itsinnovative complex genetics informatics platform with a variety of algorithmicmethods for identifying genetic features, detecting genetic pattern andconstructing classification trees."Had we performed this work like others, on simple genetics terms, we wouldnever have found the answer," said Dr. Tony Frudakis, Ph.D., CEO and CSO ofDNAPrint genomics, Inc. "It is because of our blend of computational, geneticsand mathematical expertise that we are able to tease the complex genetics of eyecolor from the data, and it is because of this expertise that RETINOME(SM) ispossible."The SNPs that the company used to construct the solution represent a smallcomponent of the company's developing PHENOME(SM) database of proprietary SNPs,which covers most of the genes involved in variable drug reactivity. "TheRETINOME(SM) solution reflects positively on the company's informaticscapabilities, the quality of its data production and its ability to managecomplex genomics datasets. "Our timely success with the RETINOME(SM) projectvalidates our data resources and analytical prowess as a real and present forcefor pharmacogenomics research and product development," said VenkateswarluKondragunta, Vice-President of DNAPrint genomics, Inc.RETINOME(SM) complements (rather than replaces) current DNA testing in themulti-million dollar forensics DNA testing market. The market for pigmentrelated disease treatments could exceed $100 Million annually. The company willnow proceed to identify a licensee for the RETINOME(SM) technology in order toeffect its rapid commercialization. RETINOME(SM) is the company's firstgenomics-based classification product, and it joins only a handful of complexgenetics predictive tools. After its licensing and validation by acommercialization partner, RETINOME(SM) is expected to provide DNAPrint's firstsubstantial source of product-derived revenue.About DNAPrint genomics, Inc.:DNAPrint genomics Inc. was founded by a team of scientists with research andcommercial experience in high-level mathematical modeling, programming andmolecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board underthe ticker symbol -- DNAP. For more information about the company, please visithttp://www.dnaprint.com/.All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities ExchangeAct as amended. Such statements are subject to risks and uncertainties thatcould cause actual results to differ materially from those projected, including,but not limited to, uncertainties relating to technologies, product development,manufacturing, market acceptance, cost and pricing of DNAPrint's products,dependence on collaborations and partners, regulatory approvals, competition,intellectual property of others, and patent protection and litigation. DNAPrintgenomics, Inc. expressly disclaims any obligation or undertaking to releasepublicly any updates or revisions to any forward-looking statements containedherein to reflect any change in DNAPrint's expectations with regard thereto orany change in events, conditions, or circumstances on which any such statementsare based. Inquiries please contact: Tim Wilkins, 941/341-0136 Or Carrie Castillo, 941/366-3400 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X44344435SOURCE DNAPrint genomics, Inc.CONTACT: Tim Wilkins, +1-941-341-0136, or Carrie Castillo, +1-941-366-3400, both of DNAPrint genomics, Inc.URL: http://www.dnaprint.comhttp://www.prnewswire.comCopyright (C) 2001 PR Newswire. All rights reserved.KEYWORD: FloridaINDUSTRY KEYWORD: MTC BIOSUBJECT CODE: PDT
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra